About
Leadership
Programs
Disease
Partnering
News
Contact Orbus
PRIVACY POLICY

Orbus Therapeutics

About
Leadership
Programs
Disease
Partnering
News
Contact Orbus
PRIVACY POLICY
Teresa Long
December 23, 2020

Orbus Therapeutics Receives U.S. Patent for Eflornithine Formulations

Teresa Long
December 23, 2020
Read full release
Newer PostOrbus Therapeutics Announces Positive Outcome of Pre-Planned Interim Futility Analysis for Phase 3 Eflornithine STELLAR Study
Older PostOrbus Therapeutics Expands Series A Financing to $71 Million to Support Ongoing STELLAR Phase 3 Study in Rare Brain Cancer
Back to Top
About
Leadership
Board of Directors
Product Candidate
Programs
Disease
Partnering
News
Contact Us
Privacy Policy

Orbus Therapeutics  |  2479 E. Bayshore Road, Suite 105  |  Palo Alto, CA 94303  |  650-656-9440

Copyright © Orbus Therapeutics, Inc.  ALL RIGHTS RESERVED